TDP2: A Potential Drug Target and Biomarker for TNF Receptor-Associated Protein

Target Name: TDP2

NCBI ID: G51567

TDP2

Other Name(s): TRAF and TNF receptor-associated protein | MGC111021 | tyrosyl-DNA phosphodiesterase 2 | TYDP2_HUMAN | EAP2 | epididymis secretory sperm binding protein | tyr-DNA phosphodiesterase 2 | RP1-30M3.3 | TT

TDP2: A Potential Drug Target and Biomarker for TNF Receptor-Associated Protein

Tumor necrosis factor-alpha (TNF) and transforming growth factor-beta (TGF-β) are two key cytokines that play crucial roles in the regulation of cellular processes, including inflammation, cell survival, and angiogenesis. Their production and regulation are tightly controlled by the transforming growth factor receptor 2 (TGF-R2) and its downstream targets, including the transcription factorRunx (RUNX), runx-related transcription factor1 (RXR1), and TDP2. TDP2 is a key regulator of TGF-R2 signaling and has been implicated in a wide range of physiological processes, including cancer, inflammation, and neurodegeneration.

Recent studies have identified TDP2 as a potential drug target and biomarker for a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. In this article, we will review the current literature on TDP2 and its potential as a drug target and biomarker.

Cytokine Signaling

TNF and TGF-β are cytokines that play central roles in the regulation of cellular processes, including inflammation, cell survival, and angiogenesis. These cytokines are produced by the cytoskeleton and have been shown to promote the recruitment of immune cells to the site of injury or infection, and to regulate the production of pro-inflammatory cytokines. The cytoskeleton is a complex structure that is involved in the regulation of cell shape and movement, and is composed of a variety of cytoskeleton components, including microtubules, filaments, and organelles.

TGF-R2 Signaling

TGF-R2 is a cytoskeleton-associated protein that is involved in the regulation of cellular processes, including cell growth, differentiation, and inflammation. TGF-R2 is a transmembrane protein that is characterized by a large extracellular domain and a unique N-terminal region that contains a nucleotide-binding oligomerization domain (NBO domain) and a catalytic domain. The NBO domain is responsible for the formation of a binary complex with the cytoskeleton, while the catalytic domain is involved in the regulation of TGF-R2 activity.

TGF-R2 signaling is dependent on the activity of several transcription factors, including Runx, RXR1, and TDP2. Runx and RXR1 are nuclear transcription factors that are involved in the regulation of cell growth and differentiation, while TDP2 is a protein that is involved in the regulation of TGF-R2 activity. TDP2 has been shown to play a central role in the regulation of TGF-R2 signaling by promoting the formation of the NBO-TGF-R2 complex and regulating the activity of TGF-R2.

Drug Targeting

TDP2 is a protein that is involved in the regulation of TGF-R2 signaling, and as such, it is a potential drug target for a variety of diseases. Several studies have shown that inhibition of TDP2 activity can lead to the inhibition of TGF-R2 signaling, and that this can have a wide range of effects, including the regulation of cellular processes, such as cell growth, differentiation, and inflammation.

In addition to its effects on TGF-R2 signaling, TDP2 has also been shown to play a role in the regulation of several other cellular processes, including the regulation of cell adhesion, the regulation of the cytoskeleton, and the regulation of cell survival. This makes TDP2 a potentially promising drug target for a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

Biomarker

TDP2 is also a potential biomarker for a variety of diseases. The regulation of TGF-R2 signaling by TDP2 is known to have a wide range of effects on cellular processes, including the regulation of cell growth, differentiation, and inflammation. This makes TDP2 a potentially promising biomarker for a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

Some studies have shown that the levels of TDP2 are significantly elevated in a variety of diseases, including cancer, and that this increase in TDP2 is associated with the development and progression of these diseases. For example, studies have shown that TDP2 levels are elevated in breast cancer, and that this increase in TDP2 is associated with the development and progression of this disease.

Conclusion

In conclusion, TDP2 is a protein that is involved in the regulation of TGF-R2 signaling and has been shown to play a role in a wide range of physiological processes, including cancer, inflammation, and neurodegeneration. As such, TDP2 is a potentially promising drug target and biomarker for a variety of diseases. Further research is needed to fully understand the effects of TDP2 inhibition on TGF-R2 signaling and to determine the best way to use TDP2 as a drug or biomarker.

Protein Name: Tyrosyl-DNA Phosphodiesterase 2

Functions: DNA repair enzyme that can remove a variety of covalent adducts from DNA through hydrolysis of a 5'-phosphodiester bond, giving rise to DNA with a free 5' phosphate. Catalyzes the hydrolysis of dead-end complexes between DNA and the topoisomerase 2 (TOP2) active site tyrosine residue. The 5'-tyrosyl DNA phosphodiesterase activity can enable the repair of TOP2-induced DNA double-strand breaks/DSBs without the need for nuclease activity, creating a 'clean' DSB with 5'-phosphate termini that are ready for ligation (PubMed:27099339, PubMed:27060144). Thereby, protects the transcription of many genes involved in neurological development and maintenance from the abortive activity of TOP2. Hydrolyzes 5'-phosphoglycolates on protruding 5' ends on DSBs due to DNA damage by radiation and free radicals. Has preference for single-stranded DNA or duplex DNA with a 4 base pair overhang as substrate. Acts as a regulator of ribosome biogenesis following stress. Has also 3'-tyrosyl DNA phosphodiesterase activity, but less efficiently and much slower than TDP1. Constitutes the major if not only 5'-tyrosyl-DNA phosphodiesterase in cells. Also acts as an adapter by participating in the specific activation of MAP3K7/TAK1 in response to TGF-beta: associates with components of the TGF-beta receptor-TRAF6-TAK1 signaling module and promotes their ubiquitination dependent complex formation. Involved in non-canonical TGF-beta induced signaling routes. May also act as a negative regulator of ETS1 and may inhibit NF-kappa-B activation

The "TDP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TDP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets